Pascal Soriot, head of AstraZeneca has been calling on the government for the purpose of providing access to the corona virus vaccine of AstraZeneca known as Evusheld and he said that, it has been a sad situation that, the United Kingdom has been one of the few developed nations, which has not ordered the drug that is designed for the people with poor immune systems.
The comments from Pascal Soriot has come as the company has been flagging up decreasing the sales of the novel corona virus vaccine, which has been developed with the University of Oxford. The strong performances by the several other medicines for diabetes, cancer and several other conditions catapulting the total sales 60 percent higher to around 11.4 billion dollars in the first three months of 2022 in spite of the covid-19 pandemic affecting the rates of cancer diagnosis.
In April 2022, the company has received the United Kingdom regulatory approval for the company’s long-acting corona virus antibody treatment known as Evusheld, in a boost to the company’s novel corona virus portfolio. Aiming at the prevention of the corona virus infections in the immunocompromised people, who cannot be vaccinated and Evusheld had also been approved in the United States, France and several other countries.
The boss of AstraZeneca said that, the United Kingdom has probably been one of the rare developed countries in the world that has not ordered Evusheld and he also said that, they had been at greater risk now that the novel corona virus restrictions have been removed.